Algert Global LLC increased its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 393.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,131 shares of the medical instruments supplier's stock after purchasing an additional 8,877 shares during the quarter. Algert Global LLC's holdings in Insulet were worth $2,591,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of PODD. Baillie Gifford & Co. increased its stake in shares of Insulet by 20.7% in the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock valued at $529,669,000 after buying an additional 389,639 shares during the period. Clearbridge Investments LLC boosted its holdings in Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier's stock valued at $270,364,000 after acquiring an additional 75,526 shares during the last quarter. American Century Companies Inc. increased its position in Insulet by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier's stock valued at $178,728,000 after purchasing an additional 139,246 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock worth $148,091,000 after purchasing an additional 193,839 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Insulet in the 2nd quarter worth approximately $99,978,000.
PODD stock opened at $266.42 on Wednesday. The firm has a market capitalization of $18.69 billion, a PE ratio of 45.62, a P/E/G ratio of 4.02 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.40. The stock's 50 day moving average is $241.97 and its 200-day moving average is $211.65.
Several equities research analysts have recently weighed in on PODD shares. Raymond James increased their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a research report on Monday, October 14th. Piper Sandler lifted their price objective on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 17th. Sanford C. Bernstein started coverage on Insulet in a report on Wednesday, November 6th. They set an "outperform" rating and a $300.00 price target on the stock. Citigroup lifted their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research note on Tuesday, October 1st. Finally, Canaccord Genuity Group increased their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a "buy" rating in a research note on Wednesday, September 25th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $253.27.
Get Our Latest Analysis on PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.